Akorn, Inc. (AKRX) Director Brian Tambi Sells 15,100 Shares
Akorn, Inc. (NASDAQ:AKRX) Director Brian Tambi sold 15,100 shares of Akorn stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $33.35, for a total value of $503,585.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Akorn, Inc. (NASDAQ:AKRX) traded up $0.07 during trading on Wednesday, reaching $32.37. The company’s stock had a trading volume of 3,091,750 shares, compared to its average volume of 2,785,376. The company has a debt-to-equity ratio of 0.92, a quick ratio of 3.17 and a current ratio of 4.16. The company has a market cap of $4,177.36, a PE ratio of 20.75, a price-to-earnings-growth ratio of 1.99 and a beta of 1.33. Akorn, Inc. has a fifty-two week low of $17.61 and a fifty-two week high of $34.00.
Several research analysts have recently commented on AKRX shares. TheStreet downgraded Akorn from a “b-” rating to a “c” rating in a report on Tuesday, August 1st. Jefferies Group LLC set a $34.00 target price on Akorn and gave the stock a “hold” rating in a research note on Sunday, October 29th. Zacks Investment Research raised Akorn from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 24th. Piper Jaffray Companies set a $34.00 target price on Akorn and gave the stock a “hold” rating in a research note on Sunday, October 22nd. Finally, Royal Bank Of Canada reissued a “hold” rating and issued a $34.00 target price on shares of Akorn in a research note on Tuesday, October 3rd. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $29.38.
Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.
Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.